FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186177557> ?p ?o ?g. }

• W3186177557 endingPage "11" @default.
• W3186177557 startingPage "1" @default.
• W3186177557 abstract "The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices. Cefiderocol is a novel siderophore cephalosporin approved in Europe for the treatment of aerobic GNB infections in adults with limited treatment options. We report pooled data for a clinical isolate set collected in England between 2014-2018.MICs were determined by broth microdilution according to International Organization for Standardization guidelines. Cefiderocol susceptibility was tested using iron-depleted cation-adjusted Muller-Hinton broth. Susceptibility rates were based on EUCAST breakpoints. In the absence of a species-specific breakpoint, pharmacokinetic/pharmacodynamic breakpoints were used.Of 1886 isolates from England [74.1% Enterobacterales (18.7% Escherichia coli, 17.2% Klebsiella pneumoniae), 25.9% non-fermenters (18.4% Pseudomonas aeruginosa, 3.7% Acinetobacter baumannii)], 98.7% were cefiderocol-susceptible. Cefiderocol susceptibility in Enterobacterales (99.0%) was significantly (P < 0.01) greater than ceftolozane/tazobactam (94.3%), but similar to meropenem (99.3%) and ceftazidime/avibactam (99.4%). Overall, cefiderocol susceptibility (98.0%) in non-fermenters was significantly (P < 0.01) higher than comparators (range, 84.5-92.4%). Susceptibility to cefiderocol was 98.3-99.6% by infection source and was significantly (P < 0.01) greater than comparators for isolates from patients with nosocomial pneumonia (cefiderocol, 98.3%; comparators range, 79.8-93.8%). Excluding intrinsically meropenem-resistant Stenotrophomonas maltophilia, 47/1846 isolates (2.5%) were meropenem-resistant. A high proportion of meropenem-resistant P. aeruginosa were susceptible to cefiderocol (95.0%). All S. maltophilia isolates (40/40) were cefiderocol-susceptible.A substantial proportion of clinical isolates from England, representing a wide range of pathogens across multiple infection sources, was cefiderocol-susceptible. Cefiderocol retained activity against meropenem-resistant strains." @default.
• W3186177557 created "2021-08-02" @default.
• W3186177557 creator A5016916593 @default.
• W3186177557 creator A5029920472 @default.
• W3186177557 creator A5033883688 @default.
• W3186177557 creator A5056645174 @default.
• W3186177557 creator A5072916169 @default.
• W3186177557 date "2021-12-01" @default.
• W3186177557 modified "2023-10-18" @default.
• W3186177557 title "In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018" @default.
• W3186177557 cites W2099303284 @default.
• W3186177557 cites W2112203749 @default.
• W3186177557 cites W2116245384 @default.
• W3186177557 cites W2123677996 @default.
• W3186177557 cites W2125699736 @default.
• W3186177557 cites W2155317724 @default.
• W3186177557 cites W2338445208 @default.
• W3186177557 cites W2472419569 @default.
• W3186177557 cites W2530661320 @default.
• W3186177557 cites W2600757231 @default.
• W3186177557 cites W2683046555 @default.
• W3186177557 cites W2766395453 @default.
• W3186177557 cites W2793390003 @default.
• W3186177557 cites W2892368225 @default.
• W3186177557 cites W2898221671 @default.
• W3186177557 cites W2900807296 @default.
• W3186177557 cites W2918206043 @default.
• W3186177557 cites W3029977503 @default.
• W3186177557 cites W3080433535 @default.
• W3186177557 cites W3092173712 @default.
• W3186177557 cites W3092383626 @default.
• W3186177557 cites W3105812155 @default.
• W3186177557 cites W3117425192 @default.
• W3186177557 cites W3119861154 @default.
• W3186177557 cites W3120434137 @default.
• W3186177557 doi "https://doi.org/10.1016/j.jgar.2021.07.014" @default.
• W3186177557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34329792" @default.
• W3186177557 hasPublicationYear "2021" @default.
• W3186177557 type Work @default.
• W3186177557 sameAs 3186177557 @default.
• W3186177557 citedByCount "7" @default.
• W3186177557 countsByYear W31861775572021 @default.
• W3186177557 countsByYear W31861775572022 @default.
• W3186177557 countsByYear W31861775572023 @default.
• W3186177557 crossrefType "journal-article" @default.
• W3186177557 hasAuthorship W3186177557A5016916593 @default.
• W3186177557 hasAuthorship W3186177557A5029920472 @default.
• W3186177557 hasAuthorship W3186177557A5033883688 @default.
• W3186177557 hasAuthorship W3186177557A5056645174 @default.
• W3186177557 hasAuthorship W3186177557A5072916169 @default.
• W3186177557 hasBestOaLocation W31861775571 @default.
• W3186177557 hasConcept C104317684 @default.
• W3186177557 hasConcept C176947019 @default.
• W3186177557 hasConcept C2775933652 @default.
• W3186177557 hasConcept C2776315533 @default.
• W3186177557 hasConcept C2776352461 @default.
• W3186177557 hasConcept C2776968632 @default.
• W3186177557 hasConcept C2777058267 @default.
• W3186177557 hasConcept C2777287306 @default.
• W3186177557 hasConcept C2777637488 @default.
• W3186177557 hasConcept C2778523567 @default.
• W3186177557 hasConcept C2779375183 @default.
• W3186177557 hasConcept C2780950330 @default.
• W3186177557 hasConcept C2781463711 @default.
• W3186177557 hasConcept C4937899 @default.
• W3186177557 hasConcept C501593827 @default.
• W3186177557 hasConcept C523546767 @default.
• W3186177557 hasConcept C54355233 @default.
• W3186177557 hasConcept C547475151 @default.
• W3186177557 hasConcept C64778159 @default.
• W3186177557 hasConcept C86803240 @default.
• W3186177557 hasConcept C89423630 @default.
• W3186177557 hasConcept C94665300 @default.
• W3186177557 hasConceptScore W3186177557C104317684 @default.
• W3186177557 hasConceptScore W3186177557C176947019 @default.
• W3186177557 hasConceptScore W3186177557C2775933652 @default.
• W3186177557 hasConceptScore W3186177557C2776315533 @default.
• W3186177557 hasConceptScore W3186177557C2776352461 @default.
• W3186177557 hasConceptScore W3186177557C2776968632 @default.
• W3186177557 hasConceptScore W3186177557C2777058267 @default.
• W3186177557 hasConceptScore W3186177557C2777287306 @default.
• W3186177557 hasConceptScore W3186177557C2777637488 @default.
• W3186177557 hasConceptScore W3186177557C2778523567 @default.
• W3186177557 hasConceptScore W3186177557C2779375183 @default.
• W3186177557 hasConceptScore W3186177557C2780950330 @default.
• W3186177557 hasConceptScore W3186177557C2781463711 @default.
• W3186177557 hasConceptScore W3186177557C4937899 @default.
• W3186177557 hasConceptScore W3186177557C501593827 @default.
• W3186177557 hasConceptScore W3186177557C523546767 @default.
• W3186177557 hasConceptScore W3186177557C54355233 @default.
• W3186177557 hasConceptScore W3186177557C547475151 @default.
• W3186177557 hasConceptScore W3186177557C64778159 @default.
• W3186177557 hasConceptScore W3186177557C86803240 @default.
• W3186177557 hasConceptScore W3186177557C89423630 @default.
• W3186177557 hasConceptScore W3186177557C94665300 @default.
• W3186177557 hasFunder F4320323316 @default.
• W3186177557 hasLocation W31861775571 @default.
• W3186177557 hasLocation W31861775572 @default.

• next